Court: GSK may have abused sales rules; FDA gives nod to Mylan's generic Risperdal;

> A legal battle between GlaxoSmithKline and Greek wholesalers over parallel trade in drugs--which could have implications for the price of medicine--ended with a mixed result at Europe’s top court. Report

> Mylan said Tuesday the FDA has approved its generic version of the antipsychotic Risperdal, and the company plans to start selling the drug soon. Report

> Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector. Report

> Pfizer reached a deal to transition some Exubera patients who still need inhaled insulin to MannKind's inhaled insulin product, Technosphere, which recently completed Phase III trials. Pfizer release

> Amylin Pharmaceuticals stock soared more than 4.7 percent yesterday after billionaire investor Carl Icahn increased his stake in the company to 7.33 percent. Report

> Pharmaceutical company Perrigo announced today that it has acquired drug and nutritional products maker JB Laboratories for $44 million. Perrigo release

> After seeing its fortunes rise and fall on the fate of its anemia drugs, Amgen will attempt to turn to a new page with the release of data from 25 studies devoted to its promising osteoporosis drug denosumab. Report

> By injecting stem cells extracted from bone marrow, scientists were able to coordinate the genetic response of animals, dramatically reducing the amount of brain damage triggered by a sudden interruption in the blood supply. Report

> GlaxoSmithKline says it will push pazopanib into late-stage studies for ovarian cancer after a mid-stage trial produced positive data on a key biomarker. Report

> There was a lot of action on the regulatory side of new drug discovery yesterday. We offer a list of the top hits. Report.

> Two top biotech players in Massachusetts are putting a spotlight on a controversial provision of the state's new $1 billion support program for the industry. Report

> France's NicOx has scored an eight percent bump in its stock price with data from a second pivotal trial showing that its leading painkiller hit all three primary endpoints as well as a key secondary endpoint. Report

Emerging Drug Developer: Osprey Pharmaceuticals USA. Report

And Finally... Could thinking make you fat? Maybe. A small Canadian study has found that people eat more after an intellectual exercise than they do after just sitting quietly. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.